Melatonin as an effective protector against doxorubicin-induced cardiotoxicity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 283, Issue 1 52-1, 2002, Pages

  Liu, Xuwan ^a,b   Chen, Zhongyi ^a,b   Chua, Chu Chang ^a,b   Ma, Yan Shan ^a   Youngberg, George A ^a,b   Hamdy, Ronald ^a,b   Chua, Balvin H L ^a,b,c  

^a Department of Pharmacology ^*  (United States)

^b Cecile Cox Quillen Laboratory of Geriatric Research   (United States)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

6 hydroxymelatonin; Apoptosis; Cardiac function

Indexed keywords

6 HYDROXYMELATONIN; 8 METHOXY 2 PROPIONAMIDOTETRALIN; DOXORUBICIN; DRINKING WATER; MELATONIN; MELATONIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; HEART DISEASE; HEART FUNCTION TEST; HEART PERFUSION; HEART PROTECTION; HORMONE ACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ULTRASTRUCTURE;

EID: 0036302635     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01023.2001     Document Type: Article

References (45)

1. Protective effect of melatonin against adriamycin toxicity in the rat
2. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis
3. Early and late sarcoplasmic reticulum changes in doxorubicin cardiomyopathy. An ultrastructural investigation with the zinc iodide-osmium tetroxide (ZIO) technique
4. Anthracycline cardiomyopathy monitored by morphologic changes
5. Early anthracycline cardiotoxicity
6. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice
7. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase
8. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture
9. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin
10. Melatonin receptors: Are there multiple subtypes?
11. Melatonin receptor antagonists that differentiate between the human Mella and Mellb recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML 1 presynaptic heteroreceptor
12. Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension
13. A mouse model of familial hypertrophic cardiomyopathy
14. Phycoerythrin fluorescence-based assay for reactive oxygen species
15. The significance of the metabolism of the neurohormone melatonin: Antioxidative protection and formation of bioactive substances
16. Chemistry of dexrazoxane and analogues
17. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats
18. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice
19. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity
20. Cardioxane-ICRF-187 towards anticancer drug specificity through selective toxicity reduction
21. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species
22. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin
23. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status
24. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat
25. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity
26. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
27. Acute doxorubicin cardiotoxicity: Functional, metabolic, and morphologic alterations in the isolated, perfused rat heart
28. Melatonin: A peroxyl radical scavenger more effective than vitamin E
29. Treatment of human prostate tumors PC-3 and TSU-PR 1 with standard and investigational agents in SCID mice
30. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention
31. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity
32. Plasma 6-hydroxymelatonin, 6-sulfatoxymelatonin and melatonin kinetics after melatonin administration to rats
33. Pharmacological actions of melatonin in oxygen radical pathophysiology
34. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo
35. Doxorubicin cardiotoxicity and serum lipid increase is prevented by dexrazoxane (ICRF187)
36. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
37. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect
38. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats
39. New colorimetric cytotoxicity assay for anticancer-drug screening
40. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice
41. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes
42. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice
43. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice
44. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice
45. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes